Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical evaluation of dried blood spots for ribociclib level determination
NL-OMON25336Recruiting
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoint: Agreement between ribociclib plasma levels measured by venipuncture and dried blood spot sampling. Started Sep 2019; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON25336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25336.